This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Best Biotech CEO of 2012: Your Vote Counts

BOSTON ( TheStreet) -- This year's nominees for Best Biotech CEO of 2012 all share something in common. Each of the four executives achieved great success this year, in part, by proving various naysayers -- analysts, investors and media (ahem) -- wrong.

I didn't set out choosing these finalists around a central theme. But as I thought about explaining why they all deserve kudos for a job well done this year, it occurred to me that each of these CEOs faced some significant doubts about their leadership ability or strategic decisions at some point in the past. Bio-pharma investors are well accustomed to disappointment and failure, so it's encouraging to find executives who can deliver on promises made.

This year's nominees for Best Biotech CEO are Tony Coles of Onyx Pharmaceuticals (ONXX), John Martin of Gilead Sciences (GILD - Get Report), Regeneron Pharmaceuticals' (REGN - Get Report) Leonard Schleifer and Sarepta Therapeutics' (SRPT - Get Report) Chris Garabedian.

One of these executives will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Past winners are Vertex Pharma's (VRTX) Matt Emmens and Pharmasset's Schaefer Price (2011), Dendreon's (DNDN) Mitch Gold (2010), Human Genome Sciences' Thomas Watkins (2009) and Myriad Genetics' (MYGN) Peter Meldrum (2008).

Similar to the Worst Biotech CEO of 2012, please read the following nominating summaries and vote for your favorite candidate in the interactive poll at the end of this story. Feel free to post comments if you believe a CEO deserving of acclaim was left out of the voting. I'll tally your votes and award the trophy at the end of the week.

Tony Coles, Onyx Pharmaceuticals:

Investors weren't in love with Coles' selection as CEO of Onyx in 2008. In a story I wrote about Coles that February, an institutional investor and an Onyx shareholder summed up his ambivalent feeling about the new CEO thusly:

"When I saw that Tony Coles was named Onyx's CEO, my first reaction was Tony who? Then I looked at the performance of NPS [Pharmaceuticals] during his tenure there and I got depressed."


Onyx was a one-drug company when Coles took over. While Nexavar was a commercial success in kidney and liver cancer, investors were frustrated by the company's joint venture with Bayer. Nexavar sales were growing but the dollars weren't flowing to Onyx's bottom line. The company was spending a lot of money but its pipeline was non-existent. Efforts to expand Nexavar into other cancer indications, most notably lung cancer, were failing.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
GILD $90.43 -6.80%
REGN $377.58 -3.50%
SRPT $14.68 6.40%
AAPL $93.56 -1.30%


Chart of I:DJI
DOW 17,720.33 -110.43 -0.62%
S&P 500 2,057.78 -18.03 -0.87%
NASDAQ 4,759.2590 -46.0320 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs